Issues in Bioprospecting: Lessons from the Field

Slides:



Advertisements
Similar presentations
Access to Biological Resources and Benefit sharing in India
Advertisements

Bio Prospecting Experience in Ethiopia Presented By Mesfin Bayou Legal Consultant Regional ABS Capacity-Building Workshop for Eastern and Southern African.
REGIONAL ABS CAPACITY BUILDING WORKSHOP FOR EASTERN AND SOUTHERN AFRICA ZAMBIA PRESENTATION BY LOVEMORE SIMWANDA AND RICHARD M. LUNGU.
The Drug Discovery Process
TBGRI- KANI MODEL OF BENEFIT SHARING
An Industry Perspective on Access & Benefit Sharing Tom Jacob, Senior Advisor - Global Affairs, DuPont Chair, ICC Task Force on ABS
BIO-PROSPECTING PRUNUS AFRICANA IN UGANDA By David L.N. Hafashimana (Ph.D) National Forestry Resources Research Institute (NaFORRI), UGANDA.
Regional ABS Capacity- Building Workshop for Eastern and Southern Africa, Addis Ababa October 2 nd -6 th, 2005 Bioprospecting for enzymes in protected.
Agreement on Access to, and Benefit-sharing from, Teff genetic resources Institute of Biodiversity Conservation.
LEGAL AND REGULATORY REGIME FOR ACCESS AND BENEFIT SHARING IN KENYA Presented By: Anne N. Angwenyi National Environment Management Authority (Kenya)
National Herbarium & Botanic Gardens of Malawi
Commercial Research, Biodiversity and Benefit Sharing: Exploring Best Practices for Biotrade and ABS – Windhoek, Namibia, 18 th to 20 th June 2007 The.
Anti-Malaria Consortium Dr Maureen Wolfson
PhytoTrade Africas Approach to ABS First ABS Capacity Building Workshop for Africa Cape Town, 19 th to 24 th November 2006.
WIPO Conference on Building Partnerships for Mobilizing Resources for Development Thematic Session 2 Science, Technology and Innovation for Development.
Access to and Use of Traditional Knowledge A view from industry Bo Hammer Jensen.
CONSERVATION and SUSTAINABLE USE of MEDICINAL PLANTS (CSMPP)
Session 4 - Communities of practice Natural Products Drug Discovery The ICBG Program: A view from afar* Special thanks to Joshua Rosenthal of the NIH Fogarty.
Challenges in new drug discovery in South Asia
Lecture 7 – NPs and The Pharmaceutical Industry. Artemisinin Artemisinin treats multi-drug resistant strains of malaria. It is a sesquiterpene lactone.
Melanesia Experiences in Marine Drug Discovery at University of the South Pacific” Prof. B. Aalbersberg and K.-D. Feussner CDDC, IAS, USP.
CLINICAL EVALUATION OF HERBAL REMEDIES AND MEDICINAL PLANTS Some issues GCP for new drug clinical trials in India R.Raveendran Chief Editor Indian Journal.
The Convention on Biological Diversity, access to genetic resources and IPR Yovana Reyes Tagle University of Helsinki.
Intro to Medical Ethnobotany.
“Undoing the Knot in A&BS Transactions: In Search of Amicable Solutions” Introduction Gerd Winter.
THE LAW MAKING PROCESS OF AN ACCESS AND BENEFIT SHARING REGIME IN KENYA Presented By: Anne N. Angwenyi National Environment Management Authority (Kenya)
National Botanical Research Institute, Lucknow (Herbal Technology) R&D Activities National Botanical Research Institute, Lucknow (Herbal Technology) Dr.
Experiences with implementation of Brazilian A & BS Regime and Suggestions for Reform Juliana Santilli.
Bioindustrial development for transforming Kerala into an Economic Power P. Pushpangadan National Botanical Research Institute (Council of Scientific.
Access and Benefit Sharing and the Nagoya Protocol Nashina Shariff Manager Environmental Stewardship Branch November 2014.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
How to operationalize the disclosure requirement at the national level in a manner supportive to the TRIPS Agreement and the CBD? Dr. N.S. Gopalakrishnan,
THE ROLE OF INTELLECTUAL PROPERTY RIGHTS IN PROTECTING TRADITIONAL KNOWLEDGE The Philippine Experience Presented by: Marga C. Domingo-Morales Senior Policy.
Developing Countries & Sustainable Development Srividhya Ragavan Professor of Law University of Oklahoma Law Center.
Protecting Traditional Knowledge in India March 22, 2012 Anuradha R.V. Partner, Clarus Law Associates New Delhi, India.
Bioprospection : from economics of contracts to reflexive governance Tom Dedeurwaerdere Centre for Philosophy of Law Research funded.
By Dr. P. Pushpangadan Director, National Botanical Research Institute Website: Tel./ Fax:
ABS Best Practice Standard + Handbook Sponsored by SECO Developed by: IISD, Stratos Inc., Jorge Cabrera Launch of the ABS Management Tool Side Event ABS.
INTRODUCTION TO RA.
What makes Clinical Research Ethical? Dr Enoka Corea Co-secretary, ERC Faculty of Medicine, Colombo.
Session 4: The Convention on Biological Diversity Making Access Decisions.
Global Recognition of the Indian Biotech Sector - The Road Ahead Sept 26,2003 Hyderabad.
CHALLENGES IN NEGOTIATING AND IMPLEMENTING ABS AGREEMENTS: A TEN YEAR EXPERIENCE FROM AN NGO IN CAMEROON Access and Benefit Sharing Management Tool (ABS.
Bioresources, IPR & WTO Regime in 21 st Century P. Pushpangadan National Botanical Research Institute (Council of Scientific &Industrial Research), Rana.
Protection of Traditional Knowledge -The Indian Perspective A presentation by Desh Deepak Verma, Joint Secretary, Ministry of Environment & Forests, Govt.
Biodiversity, Genetic Resources and related knowledge in India.
United Nations Environment Programme Regional Cooperation and Coordination Experiences Marieta Sakalian Programme Management/Liaison Officer Biodiversity.
Characterization, Inventory and Monitoring of trends in indigenous livestock Dr. E. D. Ilatsia D. N. Kamiti 23-Oct-15Animal Breeding and Genomics Group1.
Y. Venkateswara Rao Dabur Research Foundation. Overview  Traditional Knowledge  What can be commercialized?  Why Commercialization?  Commercialization.
P. Pushpangadan & K. Narayanan Nair National Botanical Research Institute (Council of Scientific & Industrial Research) Lucknow – , India ACCESS.
“PERUVIAN EXPERIENCE IN THE PROTECTION OF TRADITIONAL KNOWLEDGE” Presentation by Minister Counsellor Betty Berendson, Deputy Permanent Representative of.
1 PROSPECTS & REALITIES OF PLANT DRUG DEVELOPMENT IN MALAYSIA Presented by: Prof. A. N. Rao Editor-in-Chief, Journal of Tropical Medicinal Plants Malaysia.
Secretariat of the Pacific Regional Environment Programme Ninth Global Forum on Bioethics in Research Auckland, New Zealand 3-5 December, 2008 Access &
Benefit Sharing Mechanism for Traditional Knowledge Proliferation Presented by: Presented by: Deepak Sharma Gaurav Soni.
Law and Policy of Relevance to the Management of Plant Genetic Resources Session 7: IPRs II: How Intellectual Property Rights Can Affect the Daily.
Law and Policy of Relevance to the Management of Plant Genetic Resources Objectives of Day Four 1.To discuss and understand how intellectual property.
SBRAVI S.Bala Ravi M.S. Swaminathan Research Foundation India PANEL DISCUSSION: What are the perceived and historic risks associated with non-commercial.
Monitoring and reporting on the implementation of the Second Global Plan of Action for PGRFA Cairo 5-6 November 2014 Monitoring the implementation of the.
Multi-disciplinary University Traditional Health Initiative (MUTHI): Building Sustainable Research Capacity on Plants for Better Public Health in Africa.
Deriving benefits from genetic resources by Naana E. K Halm WIPO Consultant 1.
Exploring BIODIVERSITY, AGRICULTURE and CLIMATE CHANGE in NATIONAL LAWS affecting LOCAL COMMUNITIES AND INDIGENOUS PEOPLES Ambra Gobena, Esq.
Biodiversity, Access & Benefit-sharing and the Sustainable Development Goals Tomme R. Young IRIS (International Research Institute for Sustainability)
Protecting Traditional Knowledge in India
PROSPECTS & REALITIES OF PLANT DRUG DEVELOPMENT IN MALAYSIA
Drug Design and Drug Discovery
Objectives, Scope and Structure of Country Reports
Farmers’ Rights in India
1999 MOSAICC 2001 CBD BONN GUIDELINES
Nagoya Protocol on Access & Benefit Sharing Arising from the Utilization of Biological Resources GEF/UNEP-SPREP Regional Project on the Ratification of.
Module 3: Key Articles of the Nagoya Protocol on Access to Genetic Resources and Benefit-Sharing Science Places Plants People.
Presentation transcript:

Issues in Bioprospecting: Lessons from the Field P. Pushpangadan National Botanical Research Institute Rana Pratap Marg, Lucknow-226001 IUCN South Asia Regional Training Programme on Bioprospecting, Access and Benefit Sharing, NBRI, 10-12, January 2005

WHAT IS BIOPROSPECTING? Exploration of biodiversity for commercially valuable genetic and biochemical resources - Eisner 1989, Reid et al. 1993 The systematic search for genes, natural compounds, designs and whole organisms in wild life with a potential for product development by biological observation, and biophysical, biochemical and genetic methods without disruption to nature. - Nicolas Mateo et al., 2001

Bioprospecting: Major Areas Chemical prospecting Drug and pharmaceuticals Pesticides Cosmetics Food additives Other industrially valuable chemical products Gene prospecting Genetic Engineering Crop development Fermentation Cell culture Bionic prospecting Designs Sensor technologies Architecture Bioengineering Bio-modeling

Bioprospecting : Essential elements RAW OR VALUE – ADDED MATERIALS/DERIVATIVES (GENETIC RESOURCES / TK) LEAD BASED or MECHANISM BASED COLLECTION, SOURCING, ACQUISITION (Through PIC, MAT, and MTA) EXTRACTION SCREENING RANDOM PRIMARY SCREENS BIOMOLECULES – BIOLOGICAL ACTIVITY/GENES – TRAITS ISOLATION & CHARACTERIZATION STRUCTURAL ELUCIDATION TRIALS & TESTS (CLINICAL, GENETIC STABILITY, BIOSAFETY) IPR GENERATION / PROTECTION BENEFIT SHARING SECONDARY SCREENS PRODUCT DEVELOPMENT MARKETING

Bioprospecting: Major Areas Biodiversity & IPR/TK Sustainableuse Benefit sharing Bioinformatics   IPR Biotechnology Information technology Herbal Bioprospecting Conservation Drug Development Pharmaceuticals Agro-chemistry Cosmetics Proteins Enzymes New crop varieties GMOs GM Foods, Designs. etc

Elements of Natural Product Mechanism-based Screening Selection of molecular target Purification of reagents Development of assay Drug design IDENTIFICATION OF LEAD Natural product screening Synthesis & SARA studies Selection development candidate Compound bank screening Combinatorial chemical libraries

Elements of Natural Product Discovery-Random Screening ACQUISITION Raw material: field collections, culture collections, screening libraries, etc EXTRACTION PRIMARY SCREENS ISOLATION & CHARACTERIZATION STRUCTURAL ELUCIDATION PRE-CLINICAL & CLINICAL DEVELOPMENT SECONDARY SCREENS

TOXICOLOGICAL AND EFFICACY EVALUATION Prospecting for drugs and pharmaceuticals from traditional knowledge (Ethnopharmacological Approach) Bioactive Molecules Product Development & Pharmaceutics: Dosage Forms TOXICOLOGICAL AND EFFICACY EVALUATION Activity Guided Isolation Selection of Effective combinations of extracts Pharmacodynamics Bioactive Extracts Pharmacokinetics Multi-centric, Randomized, Clinical Trials Final Product Marketing & Benefit Sharing with the Traditional Communities Interaction with Traditional communities and obtaining Ethno medical information with Prior Informed Consent Selection of Potential Herbal(s)/Formulation(s) Literature Survey Development of Scientifically Validated herbal drugs/formulations Clinical Dosage forms Safety Efficacy Evaluation The Product Development Shelf Life Studies

Bioprospecting Programmes - Examples InBio – Merck Agreement: Beginning of a Bioprospecting Era Shaman Pharmaceuticals International Cooperative Biodiversity Groups (ICBG)

Bioprospecting Programmes : Examples from India CSIR Coordinated Programme on Drug Discovery (1996- ) New Millennium Indian Technology Leadership Initiative (NMITLI) – Planning Commission/CSIR(2002- ) Dept. of Biotechnology – Bioprospecting and Molecular Taxonomy Programme(1998- )

Issues of Bioprospecting Access and Benefit Sharing (ABS) Access Norms and Policies Ownership and Sovereign Rights on Biodiversity – Who owns the resources? Prior Informed Consent (PIC) – Principles and Practices Mutually Agreed Terms (MAT) Material Transfer Agreements (MTA)

Issues of Bioprospecting(Contd..) Access and Benefit Sharing (ABS) Benefit Sharing Monetary Benefits Access fees. Up – front payments. Milestone payments. Sharing of Royalties. License fees in case of commercialization. Special fees to be paid to trust funds supporting conservation and sustainable use of biodiversity. Salaries and preferential terms on mutually agreed terms. Research funding. Joint ventures. Joint ownership of relevant intellectual property rights.

Issues of Bioprospecting(Contd..) Access and Benefit Sharing (ABS) Benefit Sharing Non-monetary Benefits Sharing R&D results Collaboration in S&T and development programmes (Biotechnology) Participation in Product Development Collaboration in Education and Training Admittance to ex situ facilities and databanks Institutional Capacity Building Human Resource Development Information Exchange Contribution to Local Economy Contribution to other domestic benefits Food and Livelihood security benefits Social Recognition Joint IPRs

Issues of Bioprospecting(Contd..) Conservation of biodiversity. Sustainability of Genetic Resource Stocks Uncertainties and opportunistic behaviors Success rate of bioprospecting programmes Market Trends National and International Legal and Policy Environment Capacity Building in Biodiversity inventorying, and bioprospecting technologies Biotechnology Herbal Technology Information Technology

Issues of Bioprospecting(Contd..) Intellectual Property Rights(IPR) Protection Traditional Resource Rights of Indigenous Communities Bioethics and Biosafety Transgenics Transgenic foods Transgenic medicines

Tribal Settings in India Benefit sharing with an indigenous community (tribe) – A Case Study Tribal Settings in India India has over 70 million tribals belonging to over 550 communities inhabiting in 5000 villages located in and around forests region of the country. About 217 different dialects are spoken by tribal communities in India.

Tribal Settings in India Benefit sharing with an indigenous tribe (Contd..) Tribal Settings in India Population of the individual tribe is as large as about 5 million in Madhya Pradesh and as small as 21 like Onges of Andaman Islands. The tribals in the country occupy about 18.74% of the total area of the country, mainly in the hilly and forest areas of 19 states and union territories.

10000 plant species are used by tribes of India Benefit sharing with an indigenous tribe (Contd..) 10000 plant species are used by tribes of India 8000 Medicinal Total 10000 species 325 3500 Edible 425 Pesticides 1000 Others 550 Fibre Gums, Resins & Dyes

INDIAN SYSTEMS OF MEDICINE Benefit sharing with an indigenous tribe (Contd..) INDIAN SYSTEMS OF MEDICINE 8000 species Ayurveda 900 sp. Unani 700 sp. THE INDIAN FLORA (ca 17500 species) Siddha 600 sp. Modern 30 sp. Amchi 250 sp.

Benefit sharing with an indigenous tribe (Contd..) The Kani experiment During the course of an ethnobotanical exploration, Pushpangadan and co-workers (1987) came across an interesting use (anti-fatigue) of a lesser known wild plant while conducting the study on the forest dwelling Kani Tribe of South Western Ghat mountains.

Benefit sharing with an indigenous tribe (Contd..) The Kani Tribe ‘Kani’, a semi-nomadic tribal community inhabits in the forested mountains in and around ‘Agasthyamalai’ of the southern Western Ghat region of India. Their population as per the 1991 census of India is 1618.

Interaction with Kani Tribe Benefit sharing with an indigenous tribe (Contd..) Interaction with Kani Tribe In December 1987, a team of scientists led by Dr. Pushpangadan was conducting an ethno-botanical survey and exploration in the Agasthya hills, of the Western Ghats in South India with the help of two young Kani men as guides. During this visit, the author and his colleagues noticed that the Kani men were not taking any food and were eating only some small dry fruits. But they were quite energetic and agile.

Interaction with Kani Tribe Benefit sharing with an indigenous tribe (Contd..) Interaction with Kani Tribe After a strenuous mountain trek, the author (Pushpangadan) and colleagues got exhausted and were taking rest. Then the Kani men accompanying them offered those dry fruits saying that when consumed they would reduce fatigue and provide energy.

Scientific Investigations Benefit sharing with an indigenous tribe (Contd..) Scientific Investigations Collected adequate samples of this plant for detailed investigations at Regional Research Laboratory, (RRL), Jammu. Soon after reaching back at RRL, Jammu, Dr. Pushpangadan conducted the first scientific test to validate the Kani’s claim on the anti-fatigue property of Arogyapacha.

Benefit sharing with an indigenous tribe (Contd..) Filing of patents Three patents on the different pharmacological activities of the compounds isolated from this plant were made by RRL, Jammu.

Drug “Jeevani” was ready Benefit sharing with an indigenous tribe (Contd..) Drug “Jeevani” was ready Within a period of seven years a scientifically validated, standardized herbal formulation ‘Jeevani’ was formulated with ‘Trichopus zeylanicus’ and three other medicinal plants as its ingredients. Evaluations related to toxicity, efficacy, shelf life and clinical properties were carried out by TBGRI, and the drug was ready by the end of 1994.

Drug “Jeevani” was released Benefit sharing with an indigenous tribe (Contd..) Drug “Jeevani” was released After the necessary pharmacological evaluation and clinical study, the drug was released for commercial production.

Bottlenecks in implementation of the same Benefit sharing with an indigenous tribe (Contd..) Bottlenecks in implementation of the same However, it took almost two years to transfer this benefit to be transferred to the Kani tribe due to inherent problems of the tribe. Kani tribe is an unorganized semi-nomadic forest dwelling tribe. They later organized themselves and formed a trust with over 50% of adults from Kani Tribe as its members.

Actual transfer of money Benefit sharing with an indigenous tribe (Contd..) Actual transfer of money to Kani tribe TBGRI transferred the money due to Kani tribe (Indian Rupees 650 thousand) in Feb 1999. They are now regularly getting 50% of royalty.

Impact on Removing Poverty from this Initiative DWELLING Past Present

Impact on Removing Poverty from this Initiative LIVING CONDITIONS Past Present

Bioprospecting Contracts Any Bioprospecting contract should include: Entry of access fee Collection fee for samples collected Processing fee for processing done, if any Royalty on the final product

Contract on Access to Traditional Knowledge could include: Access or consent fee for obtaining the consent of the appropriate community for accessing closely held knowledge that is protected through a sui generis legislation An access fee for accessing information containing in biodiversity registers or other documents in the case of public domain or quazi public domain knowledge. A royalty on the final product that is developed from TK, by the bioprospector

Safeguarding IPRs of indigenous/ local communities and Benefit-sharing Survey, inventory & documentation of the indigenous knowledge system and preparation of community registers Preparation of Electronic Database (Access to Patent Office) Access to Database with prior informed consent Negotiation and signing of agreement(s) Development of marketable product/s (with S&T intervention) Commercialization of the products Benefit sharing with the indigenous/ local communities

Thank You